Several efforts have been made to limit the prevalence of intoxicating hemp products.
On April 2nd, 2024, the Iowa Senate passed a bill, House File 2605, that created restrictions and penalties for hemp products sold in the state (1). The bill was sent to Governor Kim Reynold and if signed, will limit the amount of tetrahydrocannabinol (THC) to 4 mg per serving in a hemp product with a limit of 10 mg per container, restrict the sale of hemp products to individuals 21 and older, and create other restrictions such as on the sale of alcoholic beverages containing THC (1,2).
The Iowa Hemp Act was passed in 2019 and some argue it created loopholes for the sale of unregulated hemp products and could be taking away from the state’s medical cannabis program (1). “The medical cannabidiol program actually puts an individual with a doctor to get these products, that’s the biggest distinction,” stated Senator Dan Dawson (1). “The Iowa hemp program has none of those barriers there. So if we want to protect Iowans with these products...there has to be some type of guardrails on here, to make sure that the medical cannabidiol program is the program that we can direct Iowans to when they have one of these diagnosed conditions.”
The bill passed with a 31-18 vote (1).
Similarly, Georgia also recently passed a bill regulating hemp products. On April 4th, 2024, the Georgia Senate passed a bill, SB 494, that would create regulations for hemp products, including products containing cannabidiol (CBD) (3). The bill has been sent to Governor Brian Kemp and if signed, would require several changes to the sale of hemp products, though not ban them entirely (4). SB 494 would, among several other actions, (3,4):
The Department of Agriculture would also be authorized to enforce certain criminal laws (3).
Late last month, 21 attorneys general sent a letter to Congress requesting action be taken in the upcoming reauthorization of the Farm Bill concerning the ambiguities that inadvertently allow for intoxicating hemp-derived cannabinoids (5). The letter noted the products’ potency, risk to youth, and the limited action that can be taken to contain their effects on safety, health, and the regulated cannabis markets (5). “The definition of hemp should be amended to clarify that there is no federal hemp intoxicants loophole, and the 2023 reauthorization should reaffirm that members of Congress do not intent to limit states in restrictions or regulations related to cannabinoids or any other derivatives of hemp which are deemed intoxicating,” the letter read (5).
The attorneys general of Iowa and Georgia were among those who signed the letter (5).
Related: Read our coverage of a GMP Collective webinar on safeguarding consumers in the era of intoxicating hemp and synthetic cannabinoids.
References
Cannabis, US Presidential Election 2024, and Beyond: A Roundtable Discussion, Part II
December 17th 2024With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election, including state and federal policies and possible paths forward for testing standardization. Join us in the second part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
Cannabis, US Presidential Election 2024, and Beyond: A Roundtable Discussion, Part I
December 16th 2024With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election. We discuss what drives support or opposition from both sides of the aisle, the complexities of balancing state and federal priorities, and more. Join us in the first part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
Work Smarter, Not Harder: How ASTM Standards for Cannabinoids Improve Your Operations
December 3rd 2024ASTM Standards D8557-24 and D8556-24, provide unified guidelines for GMP (Good Manufacturing Practices) and QMS (Quality Management Systems) in cannabis operations. These standards enhance compliance, product safety, and operational consistency across the industry for the benefit of operators, consumers, and other stakeholders in the industry.